This study proposes to compare 2 different methods for managing a subject with psoriasis who
has achieved good disease control, as defined by a clinical response with a Physician Global
Assessment (PGA) inferior or equal to 1 at the screening visit, on etanercept treatment.
The first method involves stopping etanercept treatment on entry into the study, with the
option to reinitiate etanercept at 50 mg once weekly after medical review and agreement
between the subject and the investigator. The second method involves continuing on
etanercept at 25 mg once weekly, with the option to increase the dose to 50 mg once weekly
after medical review and agreement between the subject and the investigator. Subjects will
be randomized into one of these two study arms.
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Pfizer Investigational Site, Besancon 25030, France
Pfizer Investigational Site, Limoges 87042, France
Pfizer Investigational Site, Lyon Cedex 03 69437, France
Pfizer Investigational Site, Nantes Cedex 01 44093, France
Pfizer Investigational Site, Nice Cedex 03 06202, France
Pfizer Investigational Site, Paris 75010, France
Pfizer Investigational Site, Pierre Benite 69495, France
Pfizer Investigational Site, Poitiers 86000, France
Pfizer Investigational Site, Reims 51100, France
Pfizer Investigational Site, Toulouse Cedex 31059, France
Pfizer Investigational Site, Berlin 10117, Germany
Pfizer Investigational Site, Bochum 44791, Germany
Pfizer Investigational Site, Erlangen 91054, Germany
Pfizer Investigational Site, Frankfurt am Main 60590, Germany
Pfizer Investigational Site, Freiburg 79104, Germany
Pfizer Investigational Site, Hamburg 20246, Germany
Pfizer Investigational Site, Osnabrueck 49078, Germany
Pfizer Investigational Site, Athens 16121, Greece
Pfizer Investigational Site, Thessaloniki 56429, Greece
Pfizer Investigational Site, Budapest 1085, Hungary
Pfizer Investigational Site, Debrecen 4012, Hungary
Pfizer Investigational Site, Miskolc 3529, Hungary
Pfizer Investigational Site, Szeged 6720, Hungary
Pfizer Investigational Site, Catania 95123, Italy
Pfizer Investigational Site, Chieti 66013, Italy
Pfizer Investigational Site, Parma 43100, Italy
Pfizer Investigational Site, Alicante 3010, Spain
Pfizer Investigational Site, Madrid 28046, Spain
Pfizer Investigational Site, Malaga 29010, Spain
Pfizer Investigational Site, Bornova / Izmir 35100, Turkey
Pfizer Investigational Site, Harrogate HG2 7SX, United Kingdom
Pfizer Investigational Site, London E11 1NR, United Kingdom
Pfizer Investigational Site, Santander, Cantabria 39008, Spain
Pfizer Investigational Site, Istanbul, Capa 34390, Turkey
Pfizer Investigational Site, Ankara, Etlik 06010, Turkey
Pfizer Investigational Site, Istanbul, Fatih 34093, Turkey
Pfizer Investigational Site, Bursa, Gorukle 16059, Turkey
Pfizer Investigational Site, Pendik, Istanbul 34890, Turkey
Pfizer Investigational Site, Alcorcon, Madrid 28922, Spain
Pfizer Investigational Site, Getafe, Madrid 28905, Spain
Pfizer Investigational Site, Ankara, Sihhiye 06100, Turkey
Pfizer Investigational Site, Abu Dhabi, UAE 51900, United Arab Emirates